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Background
There are ongoing initiatives across countries to improve prescribing efficiency. This is due to continual pressure on resources brought about by ageing populations and the continued launch of new premium priced drugs [1] [2] [3] [4] [5] . Initiatives for established drugs include multifaceted demand-side measures to increase the prescribing of low costs generics versus originators and patented products in a class [2] [3] [4] [5] [6] [7] [8] . Classes include the proton pump inhibitors (PPIs), statins and the renin-angiotensin inhibiting drugs, with the latter including both angiotensin converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) [2] [3] [4] [5] [6] [7] [9] [10] [11] [12] [13] [14] [15] [16] [17] .
The combination of low-cost generics and mutlifaceted demand-side measures has resulted in considerable savings in some European countries without compromising care [2] [3] [4] 7, 9, 10] .
As a developing and transitional country, China has also seen rapid growth in pharmaceutical expenditure, with growth averaging 16% per annum during the past decade [18] . This growth has been enhanced by increasing health insurance coverage, now covering 90% of the Chinese population [18, 19] , with the ultimate goal of universal coverage by 2020 [18, [20] [21] [22] [23] [24] [25] . A number of measures and initiatives have been introduced in China in recent years to try and moderate growth rates to help achieve universal coverage as well as help address the difficulties with seeing physicians and associated costs. These include cutting pharmaceutical prices, introducing essential medicine lists and guidelines and establishing co-payment caps [18] [19] [20] [21] [24] [25] [26] [27] . Having said this, there appear to be currently no universal measures among public insurers to monitor the quality of physician prescribing illustrated for instance by the continued high use of antibiotics and injectables [26, [28] [29] [30] [31] [32] . Pharmaceutical expenditure has been a principal target in China since it accounts for 46% of total hospital expenditure in 2010 [18] , with hospital pharmacies dispensing more than 80% of the country's total medicines [18, 26, 27, 33] . Out-of-pocket payments account for 36% of total healthcare expenditure [21] .
The principal reasons for the high level of dispensing in hospitals include patient convenience, physician recommendations, the possibility of nonstandardized prescriptions and a greater assurance of pharmaceutical quality [26] .
Drug prices are currently determined by the government (state or province) or manufacturers themselves, with actual prices subject to tenders in each province or municipality orchestrated by the local health departments [18, 19, 26] . Since 2006, the margin between the procured and retail price was fixed to approximaely15%. As a result, greatly standardizing the purchasing channels among Chinese hospitals [19, 2627, 33] . For most pharmaceuticals, government control and tendering are the principal forces to decrease prices. Market forces are enhanced by appreciable competition among generic companies, with more than 5,000 pharmaceutical manufacturers in China producing mainly generics [18] . However, there are still no formal pricing mechanisms for generics in China unlike the situation in Europe, which helped achieve generic prices as low as 2% to 10% of patent prices in some countries [2] [3] [4] [5] 7, 14, 16] . The current system in China also encourages physicians to overprescribe pharmaceuticals as well as prescribe those that provide the greatest profit to enhance their income. Hospitals also rely on revenues from medicines for their sustainability. This combination subsequently influences prescribing patterns [18, 19, 26, [32] [33] [34] [35] . Lim and colleagues also found that dispensing doctors prescribed more medicines to patients, and prescribed more originators than generic drugs [36] . This is not helped by similar patient co-payments for an originator or generic. As a result, little increase in the use of generics in China was noted in recent years [18] .
Medicines to treat cardiovascular and cerebrovascular diseases are important classes in China due to the increasing incidence and prevalence of these diseases [18] . This includes oxiracetam, which is perceived to improve learning and memory functions of patients with dementia. Jin and colleagues also recently identified cardiovascular drugs among the leading therapeutic classes by volume among hospitals in the Chongqing District of China, alongside anti-infective agents and medicines for the digestive and nervous systems [37] , with its population of 28.8 million people (2010 census). This is similar to other districts in China [38] .
This also includes over 110 traditional Chinese medicines (TCMs) used to treat these conditions despite increasing awareness of the safety problems associated with TCMs in recent years [39, 40] . TCMs generally contain yellow pigment from Carthamine or salvianolic acids, and are typically administered via injections. New TCMs continue to be made available with the active components containing for example ginseng, the root of red-rooted salvia, red ginseng, Folium Ginkgo, pseudo-ginseng and Erigeron breviscapus extract. The manufacturers of these typically apply for new medicine approval. As a result, gain exclusive approval for manufacturing which helps obtain higher procurement prices. This use of traditional medicines is despite attempts to develop guidelines and essential medicine lists in China based on published evidence; enhanced by the increased profitability from injections [18, 21, 29, 31] . [41] . However, there are still considerable incentives for physicians to prescribe expensive originators rather than cheaper generics despite initiatives to enhance INN (International Non-proprietary name) prescribing [18, 26, 29, 33, 42] .
Consequently, the aims of this study are to firstly to assess changes in the utilisation patterns of cardiovascular and cerebrovascular drugs in recent years, including traditional Chinese medicines, with increasing availability of generic drugs. Secondly, assess changes in the utilisation of selected originator and generic cardiovascular and cerebrovascular drugs over time including TCMs as well as potential factors leading to these patterns. Thirdly, assess changes in cardiovascular and cerebrovascular drug expenditure over time as well as changes in the procurement prices for generic, originator drugs and traditional Chinese medicines. This includes the influence of price reductions as well as potentially increasing competition as more generics become available. Lastly, suggest potential future reforms that China could consider to enhance the rational use of medicines as well as obtain further price reductions.
Methods
This was an observational uncontrolled retrospective study of prescriptions between 2006 and 2012 [43] . This methodology was chosen since there have been multiple supply-and demand-side measures in China and its various Districts during this period making it difficult to perform an interrupted time series analysis. However where possible, we have performed simple statistical analyses such as the chi-square test.
We will firstly describe why we chose this data set for analysis before describing the methodology chosen for assessing utilisation and expenditure data.
Typically for drug utilisation analyses, data is obtained from health authorities or pharmacy databases [2] [3] [4] [5] [6] [7] 9, 10, [12] [13] [14] [15] [16] . However in China, most drug utilisation studies are performed with data from hospitals as they incorporate both inpatient and outpatient data [18, 39] . In addition, as mentioned, they account for 80% of total drugs currently dispensed in China [18, 26, 33] . Consequently, hospital procurement data is currently an optimal source of drug utilisation data in China. Accurate data on hospital tendering and procurement is especially important for this type of analysis given the profitability from medicines [29] . This data is not always available from some commercial sources, which can just provide maximum retail price data [33] . In addition, hospitals in China also procure and dispense medicines which are not included in the current reimbursement list. Consequently, comprehensive utilization and expenditure would not be picked up through analyzing reimbursed data sets from the Insurance Department.
Chongqing is a municipality directly under China's central government. In the urban district in Chongqing City, the main public general hospitals include three hospitals affiliated to the Third Military Medical University, two hospitals affiliated to Chongqing Medical University, and 10 municipal hospitals. Every hospital may include different generic drugs, but with the same originator equivalents as part of the tendering process to obtain good prices [18] .
We chose the largest hospital in Chongqing District to conduct our study as it is one of the largest hospitals in Southwest China. It can also provide comprehensive datasets on both utilization and expenditure and is a typical health care provider. The dataset was obtained from the magazine company of China Pharmacy. The company is located in Chongqing and is able to collect detailed information from large hospitals in southwest China. The data contains all individual drug information including product names, purchase dates, dosage forms, specification, manufacturers, unit prices and volumes. This is an authoritative source for drug utilisation statistics in China, which is regularly audited. We used a similar approach in previous studies [18] .
The datasets are broken down into three groups:  Originator products. These include products from multinational companies imported into China or manufactured by joint ventures in China founded by multinational pharmaceutical companies. Since these medicines have the original intellectual property and are considered by some to have better quality, they typically command a premium prices versus generics  Generic products. These are produced by enterprises with local investment, including state-owned and private enterprises. Prices are influenced by the Chinese price control policy, and these products typically face competition from a number of different manufacturers. Their quality has improved in recent years with a number of different measures to enhance manufacturing standards. For instance in 2009, all medicines on the Chinese essential medicine list were required to undergo quality sampling and testing at the provincial level at least annually and at the central level at least every three years [21] .
Good Manufacturing (GMP) standards were also revised in 2011 to further improve the quality of generic manufacturing in China [21]  Traditional Chinese medicines. Usually prepared from herbs or other traditional sources, with some preparations involve chemical substances. The main delivery route is via an injection. The characteristics of traditional Chinese medicines are multi target and multi utility. They are believed to provide comprehensive treatment of patients with chronic cardiovascular and cerebrovascular diseases enhanced by a high degree of acceptance among both physicians and patients. They are also believed for instance to improve blood circulation and remove blood stasis and activate collaterals [37] .
Volume data was derived from the quantity of drugs dispensed as we considered procurement volume equal to clinical consumption. We chose unit package data as our measurement of utilisation, e.g. one box (e.g., 10 mg × 16) or one bottle (e.g., 0.1 g × 1 ml for an injection or 1g for powder) as opposed to defined daily doses (DDDs) [44] . This is because:  there is currently no reliable source for DDDs for traditional Chinese medicines (the principal products used) with several authors using different methodologies and figures in their calculations [39]  most prescribing physicians in China use the package unit (i.e., one box or one bottle) as the charging unit when calculating their patients' expenditure. This is a similar concept to prescription items in the UK, which is a key metric among UK primary care organisations [16]  the specifications of the products typically did not change during the study period Calculations to determine procurement prices, prices per unit and overall expenditure were based on Chinese currency yuan (CNY). There was no allowance for inflation or deflation as we wanted to compute actual changes over time as a result of the tendering process. This is in line with previous studies [2] [3] [4] [5] [6] [7] 9, 10, [12] [13] [14] [15] [16] . We have also not converted CNY data to either US$ or Euros during the course of the study as we did not want the pricing data influenced by currency fluctuations, especially during the recent financial crises in Europe and the US.
In addition to overall utilisation and expenditure data, we also analysed several individual products separately to improve our understanding of the situation in China. For this, we typically chose to analyse in detail individual products with an average purchase volume of 1,000 packs per month or a procurement price higher than CNY 20, or a total annual value over CNY 1 million.
Results

Utilisation (general)
Total utilisation of drugs to treat cerebrovascular and cardiovascular diseases increased 3. NB Ligustrazine is included separately although it may also be considered a Chinese herbal medicine.
Utilisation measured in package units. Fold = times, e.g.4.0 fold = 4 times Analysis of the 12 single products meeting our definition showed an increase in the utilisation of both originators and generics. However, there was variable utilisation of generics with overall utilisation stabilising at 29% to 31% of total utilisation for these 12 cardiovascular products in recent years (Table 2 . Table 1A in the Appendix contains more detailed analysisbroken down by 6 month periods). 
Utilisation measured in package units
Procured expenditure (general)
Total procurement expenditure on cardiovascular and cerebrovascular medicines increased NB. We acknowledge the procurement of telmisartan was less than 1millionCNY/ year. However, included in view of the rapid rise in recent years
However, there was a mixed picture regarding procurement prices for generics and originators among the principal 12 products over time (Table 3 . More detailed analysis in Table 2A ). In general, procurement prices for both originators and generics decreased over time, although this was not universal. 
Specific classes and products
-Adrenergic receptor blockers
Nogenerics were procured for either of the two higher volume beta blockers over time (Table   2 ).
There was an increase in the utilisation of esmolol hydrochloride injections during part of the 
Calcium channel blockers
There was variable utilisation of generic versus originator calcium channel blockers. Utilisation of amlodipine and felodipine increased whilst utilisation of nifedipine decreased (Tables 2 and   1A ).
There was increasing utilisation of both generic and originator amlodipine besylate (2.5mg x 14 tablets) over time. However, there was no significant difference between the utilisation of either the generic or originator during the study period (P>0.05).
There were generally stable pack prices during this period (( Figure 5 , Tables 3 and 2A ). There was decreasing utilisation of generic sustained release tablet nifedipine in the last half of 2012. In the same period, procurement prices decreased ( Figure 6 ). There was a corresponding increase in the consumption of the originator (Tables 2 and 1A) . This led to a significant difference in the utilisation of originator vs. generic nifedipine during the course of the study (p<0.005 using the chi-square test).
There was an overall 59% price differential (expenditure/ unit) for generic nifedipine vs. the originator by the second half of 2012 (Tables 3 and 2A ). There was increased utilisation of both generic and originator atorvastatin and simvastatin over time (Tables 2 and 1A) . Overall, there was low utilisation of generic vs. originator simvastatin at only 5% of total units during the past 2.5 years. Expenditure/ unit for generic simvastatin was only 34% and 25% originator prices in early 2006 and by the end of 2012 respectively (Table 3 and 2A) .
There was high utilisation of generic atorvastatin versus total atorvastatin over time (Tables 2   and 1A) 
Renin-angiotensin inhibiting drugs
Generally, ARBs were more prescribed than ACEIs (Table 2 ). There was variable utilisation of generic renin-angiotensin inhibiting drugs over time (Tables 2 and 1A ). The utilisation of generic irbesartan and telmisartan increased over the study period whilst the utilisation of generic valsartan remained low. Overall, there were no significant difference in the evolution of (Table 1) . This was increasingly the injection ( Figure 10 ), which had a higher relative price than the capsules. 
Discussion
We will initially discuss utilisation and expenditure patterns in the Chongqing District including general findings as well as those for traditional Chinese medicines. Secondly, suggest the implications for the utilisation and expenditure for domestically produced products. Finally, we will suggest potential future reforms that could be considered by the authorities in China.
These are based on successful measures among Western European countries, who have already achieved equitable and comprehensive healthcare for their citizens. However, we are aware that any future demand-side measures will have only limited success unless the perverse incentives for physicians and hospitals are substantially reduced, e.g. addressing physician salaries who currently earn 5000 CNY (US$780) a month or less [42] .
Firstly, as expected, there was an appreciable increase in the utilisation and expenditure on medicines to treat cardiovascular and cerebrovascular diseases in the Chongqing District of China between 2006 and 2012 (Figures 1 and 2, Table 1 ). We believe this considerable increase can be attributed to many factors. These include urbanization, an aging population, the expanding scope of medical insurance and improving living standards. However, we are unable to comment further without specific research. This increase though mirrors the considerable increase in utilisation of statins and renin-angiotensin inhibiting drugs seen among Western European countries during the past decade [2] [3] [4] 6, 7, [9] [10] [11] [14] [15] [16] Authorities across countries have generally cut drug prices when faced with higher than expected expenditure or following a financial crisis [47] [48] [49] [50] . China is no exception. The main measures introduced by the authorities to try and contain drug expenditure have been price reductions. This has been seen in practice especially for the generics apart from a minority of situations (Tables 3 and 2A) , with some price reductions mirroring those among Western European countries [4, 9, 15] . However, price reduction polices implemented in isolation have not been effective in containing overall drug expenditure ( Figure 2 ). These findings are similar to those of other authors in China [18, 31, 33] as well as other Asian countries. For instance in South Korea, policies concentrating on price controls without addressing demand-side measures did not achieve their desired result [49, 51] .
Secondly, we believe the considerable growth in the utilisation and expenditure on traditional Chinese medicines (Figures 1 and 2 , Table 1 ) is an important finding. Traditional Chinese medicines accounted for 57% of total procured expenditure by the end of 2012. We believe this increase may have been facilitated by the launch of new products with higher prices, relatively limited competition, and the fact that these are typically administered by injection [29, 31, 41] . However, the lack of published data for many of these products, coupled with their high relative prices, suggests continued irrationality in prescribing in China despite the development of essential medicine lists [21] .
Concerns with irrationality in prescribing are further endorsed by the continued growth in the utilisation of originator medicines despite generics being available at reduced prices, which can be substantial (Tables 2 and 3 , 1A and 2A). The reduction in the price of generics over time mirror some of those seen among Western European countries for ARBs and statins [1] [2] [3] [4] [5] when compared with earlier originator prices (Tables 3 and 2A ). This suggests competition among generic companies has helped reduce procurement prices over time. However, hospitals and authorities will only realise the savings if this price reduction is accompanied by their appreciably increased utilisation where generics are available for procurement. Such activities could be facilitated by enforcement of the Prescription Management Ordinance in 2007 specifying that prescriptions should be written by INN [18, 26] , especially with recent regulations improving the quality of generic medicines in China [21] . High voluntary INN prescribing rates of 98% to 99% have been achieved among a range of products and classes in Scotland through a variety of demand-side measures [2, 9, 10] .
Thirdly, we believe based on our findings that there appear to be four different models in operation for domestically produced pharmaceuticals (Table 5 ).  A small decrease in the procured price per pack, e.g.10%, did not appear to generally change utilisation trends. There may also be an increase  We believe this was because the whole supply chain including manufacturers and prescribing doctors could adjust their profitability mix accordingly  This is illustrated by generic benazepril and telmisartan as well as both originator and generic atorvastatin with increased utilisation over time despite limited decreases in procurement expenditure/ unit (Tables 2 and 3, 1A and 2A) 3  Some drugs maintained a relatively high price during the study period and their consumption substantially increased, e.g. originator metoprolol and bisoprolol with the procurement price of metoprolol increasing during the study period (Tables 2 and 3 , 1A and 2A)  This was also seen for oxiracetam  Other products with a relatively stable price over time also increased their volume in line with market growth, e.g. amlodipine besylate tablet ( Figure 5) and cinepazide maleate injection (before its severe side effect became broadly known)
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 There appears to be a "CNY 20 phenomenon", i.e. when the procurement price per pack drops to near or below CNY 20, utilization rates usually decreased (or at least stopped increasing)  Examples include generic nifedipine (Figure 6 ), generic enalapril and generic simvastatin Consequently, we believe we can speculate on drug utilisation patterns based on these combined findings. Traditional Chinese medicines have generally been preferred first for treatment. This is followed by originators and generics with relatively procurement high prices.
One generic medicine in each class typically retains reasonable utilisation, e.g. amlodipine, atorvastatin and irbesartan (Table 2) (Table 5) .
However, we acknowledge that we will have to perform specific quantitative and qualitative research with defined hypotheses before we can provide specific guidance on drug utilisation patterns alongside changes in expenditure.
With respect to the future, potential measures to enhance patient access to medicines without prohibitive increases in expenditure include enhancing INN prescribing as preciously described. They also include additional measures to further lower the price of generics given some of the low prices seen in Europe [2, 3, 7, 10] . Alongside this, there must also be measures to enhance the rational use of medicines, which builds on the essential medicine list concept [21] . This includes encouraging the preferential prescribing of evidenced based low cost and equally effective generics versus more expensive originators. Another potential measure is to restrict prescribing choices within a class. As a result, enhance physician familiarity with the medicines they prescribe. This could potentially reduce adverse drug reactions and drug: drug [52] [53] [54] [55] . Research findings have also shown that increased adherence to the Wise List also reduces costs since medicines that have the most robust data tend to be well established medicines [52, 55, 56] . There are similar examples in Spain and Scotland [9, 10, 53] .
Other initiatives include potentially introducing prescribing quality indicators, which are increasingly used in healthcare as a tool to achieve safe and quality clinical care and cost-effective therapy, as well as for professional learning, remuneration, and accreditation along with financial incentives [56] [57] [58] [59] [60] . Any developed indicators must have (a) content validity; (b) face validity, i.e. relevance, credibility & acceptability (c); concurrent validity -compared with the gold standard (d) construct validity -theoretical construct of quality and (e) predictive validity to be effective and sustainable in practice [61] .
We are already seeing a reduction in the procurement of traditional Chinese Medicines in the Chongqing District. This will now be monitored, along with the introduction of potential suggestions to further enhance the rational use of medicines. This includes addressing current perverse incentives. As a result, ascertain whether any additional measures are still needed in the future in China to further enhance access to medicines without significantly increasing overall expenditure.
We acknowledge there are some limitations in this research. These include the fact that the utilisation and procurement data was collected from just one leading hospital in one District in
China. In addition, we did not use DDDs for the reasons stated. However, we are aware that other authors have not always used DDDs in this type of research. For instance, Hoyle used a market share weighted average price to analyse cost-effectiveness [62] , and Danzon and Kim defined standard units as one tablet, one capsule, or one gram, to compare the price of products in different life cycles [63] . Despite these limitations, we believe our findings are robust and transferable across hospitals and drug classes given our choice of hospital and our methodology based on actual procurement data. However, we acknowledge that follow-up studies will be needed in this and other Districts to substantiate some of the findings.
Conclusions
Traditional Chinese medicines have occupied the largest market share by volume and expenditure in this District, with originators from multinational companies preferred to generics from local manufacturers in view of their relatively higher price. The findings also suggest that price alterations had an appreciable influence on subsequent utilisation patterns, especially when these were significantly decreased. However, further research is needed in this area before we can make any definitive statements. We do believe a number of measures are needed in China to moderate future growth of pharmaceutical expenditure whilst expanding healthcare access. Authorities must seek to enhance the rational use of medicines as well as address some of the barriers. These include addressing the current perverse incentives. This already appears to be happening with a recent reduction in the procurement of traditional NB. Utilisation measured in package units, * = 2 Specifications; ** = several manufacturers and specifications. ***= Different specification to the originator. 1H = first half of the year; 2H = second half of the year
